Table 2.

Baseline characteristics of moderate-to-severe UC patients using second-line vedolizumab or infliximab (IFX→VED and VED→IFX groups, respectively).

Biological agent	IFX→VED n = 53	VED→IFX n = 22	p-value
Male, n (%)	32 (60.4%)	14 (63.6%)	0.79
Median age, years (IQR)	38.0 (28.5 – 55.0)	41.5 (29.5 – 58.8)	0.30
First-line immunomodulator co-therapy	36 (67.9%)	8 (36.4%)	0.01
Second-line immunomodulator co-therapy	28 (52.8%)	11 (50.0%)	0.82

IFX, infliximab; IQR, interquartile range; UC, ulcerative colitis; VED, vedolizumab.